TENX Tenax Therapeutics Inc
Company Analysis
Latest News
🔴 Tenax Therapeutics is trading 5% down today
Tenax Therapeutics is trading at $1.71 (-5.00%), with no new company announcement clearly explaining the August 17, 2026 decline. - The stock remains highly...
🟢 Tenax Therapeutics is trading 5.83% up today amid rebound after Phase 3 LEVEL trial failure
Tenax Therapeutics is trading 5.83% up at $1.91, with the move appearing to be a volatile rebound following the August 10 Phase 3 LEVEL trial failure. - After...
RTW Investments Buys 10% Tenax Stake, Following 90% Stock Price Crash
RTW Investments, LP disclosed a 9.99% passive ownership stake in Tenax Therapeutics in an SEC filing on August 14, 2026. The firm reported beneficial ownership...
🟢 Tenax Therapeutics is trading 10.47% up today after LEVEL trial missed primary and secondary endpoints
Tenax Therapeutics is trading 10.47% up now at $1.90, rebounding after the August 10, 2026 collapse triggered by disappointing Phase 3 LEVEL trial results. -...
🟢 Tenax Therapeutics is trading 6.69% up today on rebound from Phase 3 LEVEL trial selloff
Tenax Therapeutics is trading 6.69% up now at $1.83, extending its rebound after the August 10, 2026 collapse caused by disappointing Phase 3 LEVEL trial...
🟢 Tenax Therapeutics is trading 5.6% up after rebound from failed Phase 3 LEVEL trial
Tenax Therapeutics is trading 5.6% up at $1.71 after rebounding from the August 10, 2026 collapse triggered by the failed Phase 3 LEVEL trial. - The study...
Tenax Therapeutics Phase 3 Trial for TNX-103 Fails to Meet Primary Endpoint
Tenax Therapeutics announced topline results from its Phase 3 LEVEL clinical trial for TNX-103 in patients with pulmonary hypertension associated with heart...
Tenax Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
Tenax Therapeutics is projected to report a Q2 2026 net loss of $0.38 per share on zero revenue, with its stock currently trading at approximately $1.38...
Tenax Therapeutics Plunges 85%, Failing Phase 3 Trial for Heart Drug
Tenax Therapeutics reported that its Phase 3 LEVEL trial for TNX-103 (oral levosimendan) failed to meet its primary endpoint. The study showed no statistically...